Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Trial Profile

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Paraganglioma; Phaeochromocytoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2017 Planned initiation date changed from 21 Aug 2017 to 23 Aug 2017.
    • 15 Aug 2017 Planned initiation date changed from 18 Aug 2017 to 21 Aug 2017.
    • 12 Aug 2017 Planned initiation date changed from 16 Aug 2017 to 18 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top